Stock comparison
Eli Lilly
Sarepta Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
LLY
Eli Lilly
Market cap
$1T
Sector
Healthcare
SRPT
Sarepta Therapeutics
Market cap
$1.77B
Sector
Healthcare
Overall winner
Eli Lilly LLY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | LLY | SRPT | Winner |
|---|---|---|---|
| Warren Buffett | 72B | 40D | LLY |
| Benjamin Graham | 86A | 47D | LLY |
| Philip Fisher | 86A | 51C | LLY |
| Peter Lynch | 74B | 59C | LLY |
| Joel Greenblatt | 78C | 7F | LLY |
| Charlie Munger | 85A | 39D | LLY |
| Terry Smith | 77C | 33F | LLY |
Side-by-side metrics
| Metric | LLY | SRPT |
|---|---|---|
| Market cap | $1T | $1.77B |
| P/E (TTM) | 36.6x | 31.3x |
| EV/EBIT | 34.1x | - |
| ROIC (TTM) | 32.06% | -1.53% |
| Gross margin | 83.51% | 62.39% |
| Net margin | 34.98% | 2.98% |
| Revenue CAGR 5y | 23.17% | 33.03% |
| EPS CAGR 5y | 40.81% | - |
| Debt / Equity | 1.4x | 0.7x |
| Dividend yield | 0.62% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LLY leads on
- ROIC (TTM)32.06%vs -1.53%+105%
- Dividend yield0.62%vs 0.0%+100%
- Market cap$1Tvs $1.77B+100%
- Net margin34.98%vs 2.98%+91%
SRPT leads on
- EV/EBIT-vs 34.1x+112%
- Debt / Equity0.7xvs 1.4x+50%
- Revenue CAGR 5y33.03%vs 23.17%+30%
- P/E (TTM)31.3xvs 36.6x+15%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.